NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.90 -0.06 (-0.38 %) (As of 12/11/2018 04:00 PM ET)Previous Close$15.96Today's Range$15.30 - $16.0052-Week Range$12.75 - $32.28Volume5,977 shsAverage Volume39,208 shsMarket Capitalization$61.08 millionP/E Ratio5.41Dividend YieldN/ABeta0.27 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group. Receive OPNT News and Ratings via Email Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Metal mining Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPNT Previous Symbol CUSIPN/A Webwww.opiant.com Phone310-598-5410 Debt Debt-to-Equity RatioN/A Current Ratio7.87 Quick Ratio7.87 Price-To-Earnings Trailing P/E Ratio5.41 Forward P/E Ratio-3.46 P/E GrowthN/A Sales & Book Value Annual Sales$18.45 million Price / Sales3.30 Cash Flow$3.18 per share Price / Cash Flow5.00 Book Value$0.02 per share Price / Book795.00 Profitability EPS (Most Recent Fiscal Year)$2.94 Net Income$6.58 million Net Margins-187.13% Return on Equity-175.03% Return on Assets-107.02% Miscellaneous Employees11 Outstanding Shares3,830,000Market Cap$61.08 million OptionableNot Optionable Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions What is Opiant Pharmaceuticals' stock symbol? Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT." How were Opiant Pharmaceuticals' earnings last quarter? Opiant Pharmaceuticals Inc (NASDAQ:OPNT) posted its quarterly earnings results on Wednesday, November, 7th. The technology company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.21. The technology company had revenue of $4.37 million for the quarter, compared to the consensus estimate of $4.70 million. Opiant Pharmaceuticals had a negative net margin of 187.13% and a negative return on equity of 175.03%. View Opiant Pharmaceuticals' Earnings History. What price target have analysts set for OPNT? 1 analysts have issued twelve-month price targets for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' stock price to reach $42.00 in the next year. This suggests a possible upside of 164.2% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals. What is the consensus analysts' recommendation for Opiant Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals. Has Opiant Pharmaceuticals been receiving favorable news coverage? Headlines about OPNT stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave news articles about the technology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of Opiant Pharmaceuticals' key competitors? Some companies that are related to Opiant Pharmaceuticals include Fission Uranium (FCUUF), Amerigo Resources (ARREF), Rubicon Minerals (RBYCF), Jaguar Mining (JAGGF), Wealth Minerals (WMLLF), Alderon Iron Ore (AXXDF), Royal Standard Minerals (RYSMF), Silver Bull Resources (SVBL), Santa Fe Gold (SFEG), Quantum Materials (QTMM), US Gold (USAU), Atlatsa Resources (ATLRF), Avalon Advanced Materials (AVLNF), Westwater Resources (WWR) and Quaterra Resources (QTRRF). Who are Opiant Pharmaceuticals' key executives? Opiant Pharmaceuticals' management team includes the folowing people: Dr. Roger Crystal, CEO & Director (Age 42)Mr. David D. O'Toole, Chief Financial Officer (Age 59)Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 48)Dr. Phil Skolnick, Chief Scientific Officer (Age 71)Mr. Quan Vu, VP of Corp. Devel. Who are Opiant Pharmaceuticals' major shareholders? Opiant Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (4.85%), Vanguard Group Inc. (2.75%), Granite Point Capital Management L.P. (1.96%) and Brasada Capital Management LP (0.50%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Geoffrey Wolf, Kevin Pollack, Michael Sinclair, Phil Skolnick, Roger Crystal and Thomas T Thomas. View Institutional Ownership Trends for Opiant Pharmaceuticals. Which institutional investors are buying Opiant Pharmaceuticals stock? OPNT stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Granite Point Capital Management L.P., Vanguard Group Inc. and Brasada Capital Management LP. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall, David D O'toole, Kevin Pollack, Michael Sinclair and Roger Crystal. View Insider Buying and Selling for Opiant Pharmaceuticals. How do I buy shares of Opiant Pharmaceuticals? Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Opiant Pharmaceuticals' stock price today? One share of OPNT stock can currently be purchased for approximately $15.90. How big of a company is Opiant Pharmaceuticals? Opiant Pharmaceuticals has a market capitalization of $61.08 million and generates $18.45 million in revenue each year. The technology company earns $6.58 million in net income (profit) each year or $2.94 on an earnings per share basis. Opiant Pharmaceuticals employs 11 workers across the globe. What is Opiant Pharmaceuticals' official website? The official website for Opiant Pharmaceuticals is http://www.opiant.com. How can I contact Opiant Pharmaceuticals? Opiant Pharmaceuticals' mailing address is 201 SANTA MONICA BOULEVARD SUITE 500, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected] MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 182 (Vote Outperform)Underperform Votes: 189 (Vote Underperform)Total Votes: 371MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/11/2018 by MarketBeat.com StaffFeatured Article: How is Preferred Stock Different from Common Stock?